You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TCR-T therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Preclinical Research for Personalized TCR-T Therapy for Head and

Recruiting
  • Head and Neck Cancer
  • No intervention
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Jan 15, 2023

Pancreatic Cancer Trial in Guangzhou (TCR-T therapy)

Recruiting
  • Pancreatic Cancer
  • TCR-T therapy
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital
Aug 10, 2022

HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy Trial in New Brunswick (Conditioning, E7 TCR-T

Not yet recruiting
  • HPV-Associated Cervical Carcinoma
  • +16 more
  • Conditioning, E7 TCR-T cells, and aldesleukin
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 17, 2023

Pancreatic Cancer Trial in ShangHai (TCR-T Cells Injection(GB3010 Cells Injection))

Recruiting
  • Pancreatic Cancer
  • TCR-T Cells Injection（GB3010 Cells Injection）
  • ShangHai, Shanghai, China
    Ruijin Hospital Affiliated to Shanghai Jiaotong University Schoo
Sep 19, 2023

Chronic Hepatitis B Trial in Beijing (TCR-T)

Active, not recruiting
  • Chronic Hepatitis B
  • TCR-T
  • Beijing, China
    The Fifth Medical Center of PLA General Hospital
Jun 13, 2023

Nasopharyngeal Carcinoma Trial (PK Blood Collection, CAR, TCR)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • PK Blood Collection
  • +2 more
  • (no location specified)
Nov 1, 2022

Pancreatic Cancer, Pancreatic Tumors, Pancreatic Ductal Adenocarcinoma Trial in Shanghai (Cyclophosphamide, Fludarabine, Mutant

Recruiting
  • Pancreatic Cancer
  • +3 more
  • Shanghai, China
    Changhai Hospital
Jun 13, 2022

Gastric Cancer, Breast Cancer, Cervical Cancer Trial in New Brunswick (KK-LC-1 TCR-T cells, Aldesleukin 720,000 IU/kg IV every

Not yet recruiting
  • Gastric Cancer
  • +3 more
  • KK-LC-1 TCR-T cells
  • Aldesleukin 720,000 IU/kg IV every eight hours
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jul 30, 2022

Melanoma, Melanoma, Uveal, Head Neck Cancer Trial in Rotterdam (Adoptive therapy with autologous MC2 TCR T cells)

Recruiting
  • Melanoma
  • +2 more
  • Adoptive therapy with autologous MC2 TCR T cells
  • Rotterdam, Netherlands
    Erasmus Medical Center
Jun 1, 2022

Advanced Solid Tumor Trial in Beijing (YK0901 cells)

Not yet recruiting
  • Advanced Solid Tumor
  • YK0901 cells
  • Beijing, China
    Department of GI Oncology, Peking University Cancer Hospital
Jun 27, 2023

Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

Recruiting
  • Hepatocellular Carcinoma
  • SCG101
  • PD1/PD-L1 checkpoint inhibitor
  • Beijing, China
  • +3 more
May 7, 2022

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Cervical Cancer, Throat Cancer, Oropharynx Cancer Trial in New Brunswick (E7 TCR-T cells)

Not yet recruiting
  • Cervical Cancer
  • +20 more
  • E7 TCR-T cells
  • New Brunswick, New Jersey
  • +1 more
Jan 18, 2023

Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Cleveland

Not yet recruiting
  • Allogeneic Stem Cell Transplant Candidate
  • +4 more
  • Cellular therapy product
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Jul 1, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Endocrine/Neuroendocrine, NSCLC, Breast Cancer Trial run by the National Cancer Institute (NCI) (Fludarabine, Cyclophosphamide,

Recruiting
  • Endocrine/Neuroendocrine
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 24, 2022

HIV/AIDS Trial in Guangzhou (Chidamide with CAR-T or TCR-T cell therapy)

Completed
  • HIV/AIDS
  • Chidamide with CAR-T or TCR-T cell therapy
  • Guangzhou, Guangdong, China
    Guangzhou 8th People's Hospital
Jul 19, 2021

Kita-kyushu Lung Cancer Antigen 1, Human Trial run by the NCI (IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR)

Recruiting
  • Kita-kyushu Lung Cancer Antigen 1, Human
  • IL-2 (Aldesleukin)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 27, 2022

EBV Infection After Allogenic HSCT Trial in Beijing (EBV-TCR-T cells)

Recruiting
  • EBV Infection After Allogenic HSCT
  • EBV-TCR-T cells
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Nov 3, 2023

EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection Trial in Beijing (EBV-TCR-T cells)

Recruiting
  • EBV-associated Hemophagocytic Lymphohistiocytosis
  • EBV Infection
  • EBV-TCR-T cells
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Nov 12, 2023

Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer Trial in Shanghai (Fludarabine + Cyclophosphamide,

Not yet recruiting
  • Cervical Cancer
  • +6 more
  • Fludarabine + Cyclophosphamide
  • HRYZ-T101 TCR-T Cell
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 27, 2023

Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Seattle (Autologous Mesothelin-specific

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage IV Pancreatic Cancer AJCC v8
  • Autologous Mesothelin-specific TCR-T Cells
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 31, 2023

Advanced Solid Tumors Trial in Belgium, Germany, Spain (Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR)

Recruiting
  • Advanced Solid Tumors
  • Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
  • Ghent, Belgium
  • +2 more
Jun 23, 2022

Safety and Efficacy of TCR-like CAR-T Trial in Nanjing (TCR-like CAR-T)

Recruiting
  • Safety and Efficacy of TCR-like CAR-T
  • TCR-like CAR-T
  • Nanjing, Jiangsu, China
    Zhongda hospital
Jul 26, 2023

Soft Tissue Sarcoma Trial in Guangzhou, Beijing (NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy))

Recruiting
  • Soft Tissue Sarcoma
  • NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
  • Guangzhou, Guangdong, China
  • +1 more
Sep 18, 2022